| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Quality of life after immune suppressive therapy in aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Prophylaxis and management of thromboembolism in pnh patients: an italian survey |
|
Annals of Hematology & Oncology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
|
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Progress in medical therapy in aplastic anemia: why it took so long? |
|
International Journal of Hematology |
Aplastic Anemia |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. |
|
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
| Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
|
Haematologica |
Aplastic Anemia |
